4-(2,3-dichlorobenzoyl)-1-methyl-1H-pyrrole-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2,3-dichlorobenzoyl)-1-methyl-1H-pyrrole-2-carboxylic acid
• 英文别名: 4-(2,3-dichlorobenzoyl)-1-methylpyrrole-2-carboxylic acid
• 化学式: C₁₃H₉Cl₂NO₃
• mdl: MFCD02571738
• 分子量: 298.125
• InChiKey: HILCNGIFBTVKQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2,3-dichlorobenzoyl)-1-methyl-1H-pyrrole-2-carboxylic acid 在 ammonium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以24%的产率得到4-(2,3-dichlorobenzoyl)-1-methylpyrrole-2-carboxamide
  参考文献：
  名称：

  Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator

  摘要：

  Tumor cells switch glucose metabolism to aerobic glycolysis by expressing the pyruvate kinase M2 isoform (PKM2) in a low active form, providing glycolytic intermediates as building blocks for biosynthetic processes, and thereby supporting cell proliferation. Activation of PKM2 should invert aerobic glycolysis to an oxidative metabolism and prevent cancer growth. Thus, PKM2 has gained attention as a promising cancer therapy target. To obtain novel PKM2 activators, we conducted a high-throughput screening (HTS). Among several hit compounds, a fragment-like hit compound with low potency but high ligand efficiency was identified. Two molecules of the hit compound bound at one activator binding site, and the molecules were linked based on the crystal structure. Since this linkage succeeded in maintaining the original position of the hit compound, the obtained compound exhibited highly improved potency in an in vitro assay. The linked compound also showed PKM2 activating activity in a cell based assay, and cellular growth inhibition of the A549 cancer cell line. Discovery of this novel scaffold and binding mode of the linked compound provides a valuable platform for the structure-guided design of PKM2 activators. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.05.004
• 作为产物：
  描述：

  2-吡咯甲酸甲酯 在 aluminum (III) chloride 、 sodium hydride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 4-(2,3-dichlorobenzoyl)-1-methyl-1H-pyrrole-2-carboxylic acid
  参考文献：
  名称：

  高通量筛选和细胞外相关激酶5（ERK5）抑制剂的命中验证

  摘要：

  细胞外相关激酶5（ERK5）是癌症治疗的有希望的目标。基于IMAP FP渐进结合系统，针对ERK5开发了高通量筛选，并用于从57 617种化合物的文库中鉴定命中。筛选命中明显有四个不同的化学系列。命中的重新合成和重新测定表明，一个系列没有返回活性化合物，而三个系列返回了活性命中。结构活性研究表明，4-苯甲酰基吡咯-2-羧酰胺药效团具有很好的进一步开发潜力。鉴定了最小的激酶结合药效基团，关键实例证明了对ERK5的选择性优于p38α激酶。

  DOI：

  10.1021/acscombsci.5b00155

文献信息

• High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors
  作者：Stephanie M. Myers、Ruth H. Bawn、Louise C. Bisset、Timothy J. Blackburn、Betty Cottyn、Lauren Molyneux、Ai-Ching Wong、Celine Cano、William Clegg、Ross. W. Harrington、Hing Leung、Laurent Rigoreau、Sandrine Vidot、Bernard T. Golding、Roger J. Griffin、Tim Hammonds、David R. Newell、Ian R. Hardcastle

  DOI：10.1021/acscombsci.5b00155

  日期：2016.8.8

  The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57 617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active

  细胞外相关激酶5（ERK5）是癌症治疗的有希望的目标。基于IMAP FP渐进结合系统，针对ERK5开发了高通量筛选，并用于从57 617种化合物的文库中鉴定命中。筛选命中明显有四个不同的化学系列。命中的重新合成和重新测定表明，一个系列没有返回活性化合物，而三个系列返回了活性命中。结构活性研究表明，4-苯甲酰基吡咯-2-羧酰胺药效团具有很好的进一步开发潜力。鉴定了最小的激酶结合药效基团，关键实例证明了对ERK5的选择性优于p38α激酶。
• Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator
  作者：Yumi Matsui、Isao Yasumatsu、Takashi Asahi、Takahiro Kitamura、Kazuo Kanai、Osamu Ubukata、Hitoshi Hayasaka、Sachiko Takaishi、Hiroyuki Hanzawa、Shinichi Katakura

  DOI：10.1016/j.bmc.2017.05.004

  日期：2017.7

  Tumor cells switch glucose metabolism to aerobic glycolysis by expressing the pyruvate kinase M2 isoform (PKM2) in a low active form, providing glycolytic intermediates as building blocks for biosynthetic processes, and thereby supporting cell proliferation. Activation of PKM2 should invert aerobic glycolysis to an oxidative metabolism and prevent cancer growth. Thus, PKM2 has gained attention as a promising cancer therapy target. To obtain novel PKM2 activators, we conducted a high-throughput screening (HTS). Among several hit compounds, a fragment-like hit compound with low potency but high ligand efficiency was identified. Two molecules of the hit compound bound at one activator binding site, and the molecules were linked based on the crystal structure. Since this linkage succeeded in maintaining the original position of the hit compound, the obtained compound exhibited highly improved potency in an in vitro assay. The linked compound also showed PKM2 activating activity in a cell based assay, and cellular growth inhibition of the A549 cancer cell line. Discovery of this novel scaffold and binding mode of the linked compound provides a valuable platform for the structure-guided design of PKM2 activators. (C) 2017 Elsevier Ltd. All rights reserved.